ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years
Zhiwei Li
Matched on ORCID iD 0009-0006-2550-7686; OpenAlex author ID A5100409066. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers
Papers 5
- Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae207↗
- VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated macrophage. Last author DOI 10.1186/s12964-024-01578-x↗
- Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic Cancer. Co-author DOI 10.4143/crt.2020.330↗
- STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer. Co-author DOI 10.1042/cs20180816↗
- Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness. Co-author DOI 10.1158/1078-0432.ccr-14-2437↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yanqiao Zhang · 5 shared papers, 2015–2024 · strength 0.58
- Paper VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated mac… DOI 10.1186/s12964-024-01578-x↗
- Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
- Paper Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic… DOI 10.4143/crt.2020.330↗
- Changjie Lou · 3 shared papers, 2019–2024 · strength 0.35
- Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
- Paper Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic… DOI 10.4143/crt.2020.330↗
- Paper STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer. DOI 10.1042/cs20180816↗
- Xiaona Fan · 2 shared papers, 2024 · strength 0.34
- Paper VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated mac… DOI 10.1186/s12964-024-01578-x↗
- Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
- Hengzhen Li · 2 shared papers, 2024 · strength 0.34
- Paper VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated mac… DOI 10.1186/s12964-024-01578-x↗
- Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
- Dan Wang · 2 shared papers, 2021–2024 · strength 0.27
- Paper Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreati… DOI 10.1093/oncolo/oyae207↗
- Paper Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic… DOI 10.4143/crt.2020.330↗
- Lin Fang · 2 shared papers, 2019–2021 · strength 0.19
- Jie Lian · 2 shared papers, 2019–2021 · strength 0.19
- Tongsen Zheng · 1 shared paper, 2024 · strength 0.16
- Yang Yao · 1 shared paper, 2021 · strength 0.11
- Chao Liu · 1 shared paper, 2019 · strength 0.08
- Qi Zhao · 1 shared paper, 2019 · strength 0.08
- Jiaqi Shi · 1 shared paper, 2019 · strength 0.08
- Zengxun Li · 1 shared paper, 2019 · strength 0.08
- Dacheng Xie · 1 shared paper, 2015 · strength 0.05
- Yong Gao · 1 shared paper, 2015 · strength 0.05
- Daoyan Wei · 1 shared paper, 2015 · strength 0.05
- Jiujie Cui · 1 shared paper, 2015 · strength 0.05
- Keping Xie · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.